Avenue Therapeutics, a Fortress Biotech company, announced the first patient dosed in their phase 3 clinical trial of intravenous tramadol for the management of moderate to moderately severe pain in patients following bunionectomy surgery.

Avenue Therapeutics (NASDAQ:ATXI), a Fortress Biotech (NASDAQ:FBIO) company, announced the first patient dosed in their phase 3 clinical trial of intravenous tramadol for the management of moderate to moderately severe pain in patients following bunionectomy surgery.
As quoted in the press release:

“The commencement of the pivotal Phase 3 program is a key step in the development of IV tramadol. Based on current enrollment projections, we expect to report topline data in the second quarter of 2018,” said Lucy Lu, M.D., Avenue’s President and Chief Executive Officer. “IV tramadol, if approved, would be the only Schedule IV intravenous opioid medicine in the United States. Currently, there is a significant gap in the acute care space between pain medications for mild to moderate pain with IV acetaminophen and NSAIDS, and those for moderate to severe pain with conventional narcotics. IV tramadol has the potential to fill this gap, and provide a new therapeutic alternative for moderate to moderately severe pain with less addiction potential than conventional narcotics and a convenient step-down option to oral tramadol.”

Click here to read the full press release.

Source: globenewswire.com

addiction enrollment first patient medications pain patient patients phase 3 clinical trial therapeutics united states Pharmaceutical Investing